• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Special Reports
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Resources
    • About MassDevice
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
    • In-Depth Coverage
    • Latest News
  • Attend DeviceTalks
    • Events
      • DeviceTalks Minnesota – May 4
      • DeviceTalks Boston – May 27–28
      • DeviceTalks West
      • DeviceTalks Tuesdays
    • DeviceTalks Podcast Network
      • DeviceTalks Weekly
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Advertise
  • Subscribe
Home » Helius inks 5-year lease for new Pennsylvania headquarters

Helius inks 5-year lease for new Pennsylvania headquarters

April 11, 2017 By Fink Densford

Helius Medical

Helius Medical Technologies (TSX:HSM) said today it inked a 5-year lease on a piece of property that will serve as its corporate headquarters.

The property, 10,400 square feet of space at Newtown Commons West outside Philadelphia, will serve as corporate headquarters, a clinical research site and a physical therapy training center. The company plans to move in July 1.

“We are delighted with this move as it allows us to continue to build our clinical and commercialization infrastructure for our proprietary PoNS Therapy. We chose Newtown because it affords us access to a large pool of clinical and commercialization talent and its proximity to major international airports,” CEO Philippe Deschamps said in a press release.

In February, Helius said it closed an offering worth nearly $10 million (CAD $12.5 million) for the portable neurostimulation device it’s developing.

Helius said it plans to use the proceeds from the 6.6-million-share flotation to complete a trial of the PoNS therapy in treating mild to moderate brain injury and the launch of a new trial in multiple sclerosis and another in cognition.

Filed Under: Business/Financial News Tagged With: Helius Medical Technologies

More recent news

  • Abbott to spin out Nutrition business, cuts guidance
  • J&J launches faster Shockwave coronary catheter in the US
  • Abbott’s Cologuard Plus screening test receives CE Mark
  • Haemonetics wins FDA approval of PerQseal Elite vascular closure system
  • Medtronic announces a company president

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >
MDO ad
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2026 · Arrowfly LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy